It will hardly come as a surprise to most prostate cancer support group leaders and other prostate cancer advocates that there is a strong association between patient age and risk for side effects of radical prostatectomy. However, we now have a rather more sophisticated set of insight into such risks. Read the article.
Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.
Canada’s particle physics laboratory TRIUMF is making a push to be a future world leader in the production of a special radioactive isotope nicknamed the “rarest drug on Earth,” which can deliver devastating amounts of energy to single cancer cells, without harming nearby tissue. Read the article here.